Full text is available at the source.
Abstract
1980 semaglutide-associated cardiovascular reports were analyzed, revealing a notable association with ventricular extrasystoles.
- Ventricular extrasystoles, a type of irregular heartbeat, was the only cardiovascular term to show a significant reporting signal in both VigiBase and the FDA Adverse Event Monitoring System.
- The reporting odds ratio for ventricular extrasystoles was 1.77 (95% CI 1.31-2.40) in VigiBase and 1.37 (95% CI 1.00-1.88) in AEMS.
- These findings indicate a higher-than-expected number of reports of ventricular extrasystoles related to semaglutide compared to other cardiovascular events.
- The results suggest the need for further investigation into the relationship between semaglutide and ventricular extrasystoles using systematic monitoring techniques.
- While the analysis highlights a potential association, it does not confirm incidence or causality due to the nature of spontaneous reporting data.
Simplified